| Mrs Catherine Keyo, CRNA | |
|
7700 W Sunrise Blvd, Plantation, FL 33322-4113 | |
| (954) 939-5577 | |
| Not Available |
| Full Name | Mrs Catherine Keyo |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 16 Years |
| Location | 7700 W Sunrise Blvd, Plantation, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114464161 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | RN2258465 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Morton Hospital | Taunton, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Steward Medical Group Inc | 2860688728 | 1404 |
News Archive
Diabetes affects approximately 8 percent of the people in the United States and adults with diabetes have heart disease death rates two to four times higher than adults without diabetes, according to the American Diabetes Association. A new study shows that primary care physicians believe the barriers that put patients with uncontrolled diabetes at risk for cardiovascular disease as being patient-related or system-related.
METI, the Sarasota-based manufacturer of medical simulation products and educational software, today announced that it has begun rolling out its groundbreaking, experiential-based Nurse Residency Program at the first of many health care organizations throughout North America.
Two gene mutations that trigger a retinal disease that causes blindness in one in 5,000 males have been mapped, leading to the potential for new therapeutic treatments.
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5%. Watson's Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5% is a generic version of Alcon, Inc.'s Vigamox®, an antibiotic solution that is indicated for the treatment of bacterial conjunctivitis.
› Verified 8 days ago
| Entity Name | Ether Anesthesia Of Massachusetts Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184172769 PECOS PAC ID: 3476833492 Enrollment ID: O20161209000532 |
News Archive
Diabetes affects approximately 8 percent of the people in the United States and adults with diabetes have heart disease death rates two to four times higher than adults without diabetes, according to the American Diabetes Association. A new study shows that primary care physicians believe the barriers that put patients with uncontrolled diabetes at risk for cardiovascular disease as being patient-related or system-related.
METI, the Sarasota-based manufacturer of medical simulation products and educational software, today announced that it has begun rolling out its groundbreaking, experiential-based Nurse Residency Program at the first of many health care organizations throughout North America.
Two gene mutations that trigger a retinal disease that causes blindness in one in 5,000 males have been mapped, leading to the potential for new therapeutic treatments.
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5%. Watson's Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5% is a generic version of Alcon, Inc.'s Vigamox®, an antibiotic solution that is indicated for the treatment of bacterial conjunctivitis.
› Verified 8 days ago
| Entity Name | Steward Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043711914 PECOS PAC ID: 2860688728 Enrollment ID: O20180329001196 |
News Archive
Diabetes affects approximately 8 percent of the people in the United States and adults with diabetes have heart disease death rates two to four times higher than adults without diabetes, according to the American Diabetes Association. A new study shows that primary care physicians believe the barriers that put patients with uncontrolled diabetes at risk for cardiovascular disease as being patient-related or system-related.
METI, the Sarasota-based manufacturer of medical simulation products and educational software, today announced that it has begun rolling out its groundbreaking, experiential-based Nurse Residency Program at the first of many health care organizations throughout North America.
Two gene mutations that trigger a retinal disease that causes blindness in one in 5,000 males have been mapped, leading to the potential for new therapeutic treatments.
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5%. Watson's Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5% is a generic version of Alcon, Inc.'s Vigamox®, an antibiotic solution that is indicated for the treatment of bacterial conjunctivitis.
› Verified 8 days ago
| Entity Name | Milford Anesthesia Consultants Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437784261 PECOS PAC ID: 0446671333 Enrollment ID: O20200601002798 |
News Archive
Diabetes affects approximately 8 percent of the people in the United States and adults with diabetes have heart disease death rates two to four times higher than adults without diabetes, according to the American Diabetes Association. A new study shows that primary care physicians believe the barriers that put patients with uncontrolled diabetes at risk for cardiovascular disease as being patient-related or system-related.
METI, the Sarasota-based manufacturer of medical simulation products and educational software, today announced that it has begun rolling out its groundbreaking, experiential-based Nurse Residency Program at the first of many health care organizations throughout North America.
Two gene mutations that trigger a retinal disease that causes blindness in one in 5,000 males have been mapped, leading to the potential for new therapeutic treatments.
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5%. Watson's Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5% is a generic version of Alcon, Inc.'s Vigamox®, an antibiotic solution that is indicated for the treatment of bacterial conjunctivitis.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Catherine Keyo, CRNA 7700 W Sunrise Blvd, Plantation, FL 33322-4113 Ph: () - | Mrs Catherine Keyo, CRNA 7700 W Sunrise Blvd, Plantation, FL 33322-4113 Ph: (954) 939-5577 |
News Archive
Diabetes affects approximately 8 percent of the people in the United States and adults with diabetes have heart disease death rates two to four times higher than adults without diabetes, according to the American Diabetes Association. A new study shows that primary care physicians believe the barriers that put patients with uncontrolled diabetes at risk for cardiovascular disease as being patient-related or system-related.
METI, the Sarasota-based manufacturer of medical simulation products and educational software, today announced that it has begun rolling out its groundbreaking, experiential-based Nurse Residency Program at the first of many health care organizations throughout North America.
Two gene mutations that trigger a retinal disease that causes blindness in one in 5,000 males have been mapped, leading to the potential for new therapeutic treatments.
Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5%. Watson's Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5% is a generic version of Alcon, Inc.'s Vigamox®, an antibiotic solution that is indicated for the treatment of bacterial conjunctivitis.
› Verified 8 days ago
Ms. Melanie Eleanor Garcia, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 7700 W Sunrise Blvd, Plantation, FL 33322 Phone: 800-437-2672 | |
Amanda J Lackaye, DNP, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 7700 W Sunrise Blvd, Plantation, FL 33322 Phone: 954-939-5409 | |
Yeisirenia Padron Rodriguez, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 7700 W Sunrise Blvd, Plantation, FL 33322 Phone: 800-437-2672 | |
Alexander Brigantty - Vazquez Sr., CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 7700 W Sunrise Blvd, Plantation, FL 33322 Phone: 954-939-6588 | |
Andrene Reid, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 401 Nw 42nd Ave, Plantation, FL 33317 Phone: 954-260-8293 | |
Aloune Diana Chariot, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 7700 W Sunrise Blvd, Plantation, FL 33322 Phone: 800-437-2672 |